Personalised Functional Profiling in colorectal cancer and pancreatic cancer
Official title: Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC
Run by Luxembourg Institute of Health · NCT07500259 · Data updated 2026-11-12
This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 188 (estimated) |
| Sponsor | Luxembourg Institute of Health Government |
| Locations | 1 site (Luxembourg, Luxembourg) |
| Status | Recruiting |
| Started | September 11, 2026 |
| Main results expected | September 30, 2029 |
| Study ends | November 1, 2034 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT07500259 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with colorectal cancer or pancreatic ductal adenocarcinoma who are scheduled for surgery or biopsy and can consent to participate.
✕Probably not a fit
Patients whose tumor biology does not show a clear drug sensitivity pattern or who do not receive a matching targeted therapy may not experience a direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The ColoPan study evaluates the scientific validity, reproducibility, and predictive performance of the Personalised Functional Profiling (PFP) platform. It combines genomic sequencing with in vitro drug testing on patient-derived spheroids and organoids to generate evidence that could inform future interventional trials in CRC and PDAC. The protocol includes new enrolment of PDAC participants and uses data from prior biospecimens under a secondary use agreement. The study also examines the feasibility of implementing PFP workflows in research settings and their potential role in future trial design. Overall, the aim is to determine whether drug sensitivity profiles from PFP correlate with patient outcomes.
Why it matters
Potential benefit: If successful, the approach could help tailor cancer treatment by predicting which drugs a patient's tumor is likely to respond to.
How similar studies have gone: Previous studies in precision oncology have shown mixed results; this study tests a combined genomic and functional profiling approach to improve predictive power.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed informed consent form * ≥ 18 years of age * Willing and able to comply with the protocol for the duration of the study, including data and sample collection * Patient scheduled for surgery or biopsy (primary tumour or metastasis) PDAC Exclusion Criteria: * Female patient, pregnant, planning a pregnancy or breastfeeding. * Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * Patient unable to understand and provide informed consent and has no family member representing him/her. * Patients with any other life-threatening illness, significant organ dysfunction or any clinically relevant conditions that, according to the hospital physician, could compromise the patient's safety.
Where it's running
-
Hôpitaux Robert Schmuan
Luxembourg, Luxembourg, Luxembourg Recruiting
Study contacts
- Study coordinator: Yong Jun Kwon, phD
- Email: yong-jun.kwon@lih.lu
- Phone: +352 26970-288
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AVA6103 for advanced or metastatic FAP-positive solid tumors
This study will test whether the experimental IV drug AVA6103 is safe and can help adults with advanced or metastatic FAP-positive cancers such as pancreatic, gastric/GEJ, cervical, or vulvar adenocarcinomas.
-
AI-assisted 4D PET imaging to detect early pancreatic cancer lesions
This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.